Loading
NASDAQHealthcareMedical - Healthcare Plans
Latest quote
$27.83
+$0.28 · +1.02%
Progyny, Inc. functions as a benefits management corporation, dedicated to providing specialized solutions for fertility and broader family-building initiatives to employers throughout the United States. Its core fertility offering is characterized by a distinctive benefits plan architecture, paired with personalized, white-glove member support services and access to a meticulously chosen network of top-tier fertility specialists. Additionally, the company presents Progyny Rx, an all-encompassing pharmacy benefits solution that ensures its members can readily acquire the essential medications for their treatments. Moreover, Progyny facilitates employer-sponsored reimbursement programs to support surrogacy and adoption journeys. The company, which was established in 2008 and has its main offices in New York City, previously operated as Auxogyn, Inc. before adopting the Progyny, Inc. moniker in 2015.
Latest quote
$27.83
+$0.28 · +1.02%
After-hours
$27.90
+$0.07 · +0.25%
Oct 8, 4:49 PM ET
Regular session · ET · Market data may be delayed.
Progyny, Inc. functions as a benefits management corporation, dedicated to providing specialized solutions for fertility and broader family-building initiatives to employers throughout the United States. Its core fertility offering is characterized by a distinctive benefits plan architecture, paired with personalized, white-glove member support services and access to a meticulously chosen network of top-tier fertility specialists. Additionally, the company presents Progyny Rx, an all-encompassing pharmacy benefits solution that ensures its members can readily acquire the essential medications for their treatments. Moreover, Progyny facilitates employer-sponsored reimbursement programs to support surrogacy and adoption journeys. The company, which was established in 2008 and has its main offices in New York City, previously operated as Auxogyn, Inc. before adopting the Progyny, Inc. moniker in 2015.
Day range
Current $27.83
52-week range
Current $27.83
Regular session · ET · Market data may be delayed.
GoAI Score
Buy
Valuation
77
Undervalued
Sentiment
60
Mixed
Risk
25
Moderate Risk
Momentum
67
Gaining
Full GoAI research
Thesis, catalysts, evidence, and risk analysis.
Progyny, Inc. functions as a benefits management corporation, dedicated to providing specialized solutions for fertility and broader family-building initiatives to employers throughout the United States. Its core fertility offering is characterized by a distinctive benefits plan architecture, paired with personalized, white-glove member support services and access to a meticulously chosen network of top-tier fertility specialists. Additionally, the company presents Progyny Rx, an all-encompassing pharmacy benefits solution that ensures its members can readily acquire the essential medications for their treatments. Moreover, Progyny facilitates employer-sponsored reimbursement programs to support surrogacy and adoption journeys. The company, which was established in 2008 and has its main offices in New York City, previously operated as Auxogyn, Inc. before adopting the Progyny, Inc. moniker in 2015.
Day range
Current $27.83
52-week range
Current $27.83
Profitability as a percentage of reported revenue.
Revenue
Operating income
Net income
| Metric (USD) | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | 1.29B USD | 1.17B USD | 1.09B USD | 786.91M USD | 500.62M USD |
| Cost of goods sold | 984.18M USD | 913.86M USD | 849.8M USD | 619.59M USD | 388.49M USD |
| Gross profit | 304.48M USD | 253.36M USD | 238.8M USD | 167.33M USD | 112.14M USD |
| Selling, general, and administrative | 219.21M USD | 185.91M USD | 176.62M USD | 143.98M USD | 79.8M USD |
| Operating expenses | 219.21M USD | 185.91M USD | 176.62M USD | 143.98M USD | 79.8M USD |
| Interest income | 10.16M USD | 15.75M USD | 8.51M USD | 814K USD | 461K USD |
| Depreciation and amortization | 4.95M USD | 3.18M USD | 2.28M USD | 1.6M USD | 1.3M USD |
| Operating income | 85.28M USD | 67.46M USD | 62.18M USD | 23.34M USD | 32.34M USD |
| Net income | 58.52M USD | 54.34M USD | 62.04M USD | 30.36M USD | 65.77M USD |
Company facts updated Oct 8, 2026.
Recent quarterly results
Recent quarterly results
Third-party consensus; not a GoAI recommendation.
Average target
$35.50
27.56% upsideFunds reporting this stock among their holdings, ordered by reported position size.
iShares Core S&P Small-Cap ETFIJR126.35M0.12%104.29B USD0.06%$137.31+0.17%
Vanguard Morningstar Total Stock Market ETFVTI57.56M0.00%2.3T USD0.03%$379.56-0.39%
iShares Russell 2000 ETFIWM53.15M0.07%78.56B USD0.19%$277.57-0.05%
Avantis U.S. Small Cap Value ETFAVUV53.11M0.17%30.54B USD0.25%$120.13+0.84%
Vanguard Morningstar Small-Cap ETFVB41.45M0.02%185.3B USD0.03%$287.63+0.23%
Vanguard Morningstar Small-Cap Growth ETFVBK23.92M0.05%44.7B USD0.05%$340.59-0.48%
Vanguard Extended Market ETFVXF21.7M0.02%95.4B USD0.05%$233.13-0.15%
State Street SPDR Portfolio S&P 600 Small Cap ETFSPSM19.65M0.12%16.01B USD0.03%$53.36+0.15%iShares Core S&P Small-Cap ETFIJRVanguard Morningstar Total Stock Market ETFVTIiShares Russell 2000 ETFIWMAvantis U.S. Small Cap Value ETFAVUVVanguard Morningstar Small-Cap ETFVBVanguard Morningstar Small-Cap Growth ETFVBKVanguard Extended Market ETFVXFState Street SPDR Portfolio S&P 600 Small Cap ETFSPSMAI-generated and delayed market data for informational and educational purposes only. Not investment advice.
